Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study
Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study
复制标题
DOI：
10.1186/s13075-019-1868-0
复制
发表时间：
2019-03-27
影响因子：
4.9
通讯作者：
Lin, Chun-Yu
中科院分区：
文献类型：
--
作者：
Chen, Hung-An;Hsu, Tsai-Ching;Lin, Chun-Yu
BackgroundNo population-based study has investigated the cumulative incidence of pulmonary arterial hypertension（PAH）in patients with systemic lupus erythematosus（SLE）or the survival impact of PAH in this population. Methods我们使用了一个全国性的数据库在台湾和事件SLE患者登记2000年1月1日至2013年12月31日。采用Kaplan-Meier法估计SLE患者PAH的累积发生率和这些患者的生存率。PAH的发展的潜在预测因素确定使用考克斯比例风险回归model.ResultsOf 15,783 SLE患者，336（2.13%）开发PAH。从SLE诊断到PAH诊断的平均间隔为3.66年（标准差[SD] 3.36，范围0.1 - 13.0年）。70%的患者在发病后5年内发生PAH。PAH的3年和5年累积发生率分别为1.2%和1.8%。系统性高血压是SLE患者PAH发生的独立预测因子（校正风险比2.27，95%置信区间1.59-2.97）。SLE患者确诊PAH后1、3、5年生存率分别为87.7%、76.8%和70.1%，corresponding.ConclusionsPAH是SLE的一种罕见并发症，大多数PAH病例发生在SLE确诊后的前5年内。系统性高血压可能是SLE人群中PAH发生的危险因素。PAH诊断后的总体5年生存率为70.1%。
BackgroundNo population-based study has investigated the cumulative incidence of pulmonary arterial hypertension (PAH) in patients with newly diagnosed systemic lupus erythematosus (SLE) or the survival impact of PAH in this population.MethodWe used a nationwide database in Taiwan and enrolled incident SLE patients between January 1, 2000, and December 31, 2013. The cumulative incidence of PAH in the SLE patients and the survival of these patients were estimated by the Kaplan-Meier method. Potential predictors of the development of PAH were determined using a Cox proportional hazards regression model.ResultsOf 15,783 SLE patients, 336 (2.13%) developed PAH. The average interval from SLE diagnosis to PAH diagnosis was 3.66years (standard deviation [SD] 3.36, range 0.1 to 13.0years). Seventy percent of the patients developed PAH within 5years after SLE onset. The 3- and 5-year cumulative incidence of PAH were 1.2% and 1.8%, respectively. Systemic hypertension was an independent predictor of PAH occurrence among the SLE patients (adjusted hazard ratio 2.27, 95% confidence interval 1.59-2.97). The 1-, 3-, and 5-year survival rates of SLE patients following the diagnosis of PAH were 87.7%, 76.8%, and 70.1%, respectively.ConclusionsPAH is a rare complication of SLE and the majority of PAH cases occur within the first 5years following SLE diagnosis. Systemic hypertension may be a risk factor for PAH development in the SLE population. The overall 5-year survival rate after PAH diagnosis was 70.1%.